Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Churkina, Mario Vaneechoutte, Elena Kiprianova, Natalia Perunova, L. Avdeeva, Oleg Bukharin (2015)
Batumin—A Selective Inhibitor of Staphylococci—Reduces Biofilm Formation in Methicillin Resistant Staphylococcus aureusOpen Journal of Medical Microbiology, 05
T. Foster (2017)
Antibiotic resistance in Staphylococcus aureus. Current status and future prospectsFEMS Microbiology Reviews, 41
W. Mattheus, Ling-Jie Gao, P. Herdewijn, B. Landuyt, J. Verhaegen, J. Masschelein, G. Volckaert, R. Lavigne (2010)
Isolation and purification of a new kalimantacin/batumin-related polyketide antibiotic and elucidation of its biosynthesis gene cluster.Chemistry & biology, 17 2
Hua Xu, Todd Sullivan, Jun‐ichiro Sekiguchi, T. Kirikae, I. Ojima, Christopher Stratton, W. Mao, F. Rock, Michael Alley, F. Johnson, S. Walker, P. Tonge (2008)
Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus.Biochemistry, 47 14
R. Massengo-Tiassé, J. Cronan (2008)
Vibrio cholerae FabV Defines a New Class of Enoyl-Acyl Carrier Protein Reductase*Journal of Biological Chemistry, 283
Victoria Lee, A. O’Neill (2017)
Batumin does not exert its antistaphylococcal effect through inhibition of aminoacyl-tRNA synthetase enzymes.International journal of antimicrobial agents, 49 1
H. Bergler, Gregor Högenauer, Friederike Turnowsky (1992)
Sequences of the envM gene and of two mutated alleles in Escherichia coli.Journal of general microbiology, 138 10
J. Schiebel, Andrew Chang, Hao Lu, Michael Baxter, P. Tonge, C. Kisker (2012)
Staphylococcus aureus FabI: inhibition, substrate recognition, and potential implications for in vivo essentiality.Structure, 20 5
(2017)
Elucidation of the relative and absolute stereochemistry of the kalimantacin/batumin antibiotics
J. Schiebel, Andrew Chang, B. Merget, G. Bommineni, Weixuan Yu, Lauren Spagnuolo, Michael Baxter, Mona Tareilus, P. Tonge, C. Kisker, C. Sotriffer (2015)
An ordered water channel in Staphylococcus aureus FabI: unraveling the mechanism of substrate recognition and reduction.Biochemistry, 54 10
H. Marrakchi, W. deWolf, C. Quinn, J. West, B. Polizzi, C. So, D. Holmes, Shannon Reed, R. Heath, D. Payne, C. Rock, N. Wallis (2003)
Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK).The Biochemical journal, 370 Pt 3
D. Rozwarski, C. Vilchèze, M. Sugantino, R. Bittman, J. Sacchettini (1999)
Crystal Structure of the Mycobacterium tuberculosis Enoyl-ACP Reductase, InhA, in Complex with NAD+ and a C16 Fatty Acyl Substrate*The Journal of Biological Chemistry, 274
A. Egan, R. Russell (1973)
Conditional mutations affecting the cell envelope of Escherichia coli K-12.Genetical research, 21 2
P. Levy, M. Ollivier, M. Drancourt, D. Raoult, J. Argenson (2013)
Relation between nasal carriage of Staphylococcus aureus and surgical site infection in orthopedic surgery: the role of nasal contamination. A systematic literature review and meta-analysis.Orthopaedics & traumatology, surgery & research : OTSR, 99 6
G. Archer (1998)
Staphylococcus aureus: a well-armed pathogen.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 26 5
R. Heath, C. Rock (2000)
erratum: A triclosan-resistant bacterial enzymeNature, 406
F. Asturias, James Chadick, I. Cheung, H. Stark, A. Witkowski, A. Joshi, Stuart Smith (2005)
Structure and molecular organization of mammalian fatty acid synthaseNature Structural &Molecular Biology, 12
C. Morvan, D. Halpern, Gérald Kénanian, Amit Pathania, Jamila Anba-Mondoloni, G. Lamberet, A. Gruss, K. Gloux (2017)
The Staphylococcus aureus FASII bypass escape route from FASII inhibitors.Biochimie, 141
E. Krissinel, K. Henrick (2007)
Inference of macromolecular assemblies from crystalline state.Journal of molecular biology, 372 3
Jiangwei Yao, J. Maxwell, C. Rock (2013)
Resistance to AFN-1252 Arises from Missense Mutations in Staphylococcus aureus Enoyl-acyl Carrier Protein Reductase (FabI)*The Journal of Biological Chemistry, 288
K. Kamigiri, Yasuto Suzuki, M. Shibazaki, M. Morioka, Kenichi Suzuki, Tatsuhiro Tokunaga, B. Setiawan, R. Rantiatmodjo (1996)
Kalimantacins A, B and C, novel antibiotics from Alcaligenes sp. YL-02632S. I. Taxonomy, fermentation, isolation and biological properties.The Journal of antibiotics, 49 2
Jiangwei Yao, C. Rock (2017)
Exogenous fatty acid metabolism in bacteria.Biochimie, 141
J. Schiebel, Andrew Chang, Sonam Shah, Yang Lu, Li Liu, Pan Pan, M. Hirschbeck, Mona Tareilus, S. Eltschkner, Weixuan Yu, J. Cummings, Susan Knudson, G. Bommineni, S. Walker, R. Slayden, C. Sotriffer, P. Tonge, C. Kisker (2014)
Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor*The Journal of Biological Chemistry, 289
R. Heath, Nancy Su, C. Murphy, C. Rock (2000)
The Enoyl-[acyl-carrier-protein] Reductases FabI and FabL fromBacillus subtilis *The Journal of Biological Chemistry, 275
Hee-Soo Park, Y. Yoon, S. Jung, Rae Yun, C. Kim, Jeong Kim, J. Kwak (2007)
CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.International journal of antimicrobial agents, 30 5
W. Balemans, N. Lounis, R. Gilissen, J. Guillemont, K. Simmen, K. Andries, A. Koul (2010)
Essentiality of FASII pathway for Staphylococcus aureusNature, 463
N. Brenwald, A. Fraise (2003)
Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA).The Journal of hospital infection, 55 2
Gérald Kénanian, C. Morvan, Antonin Weckel, Amit Pathania, Jamila Anba-Mondoloni, D. Halpern, Marine Gaillard, A. Solgadi, Laëtitia Dupont, C. Henry, C. Poyart, A. Fouet, G. Lamberet, K. Gloux, A. Gruss (2019)
Permissive Fatty Acid Incorporation Promotes Staphylococcal Adaptation to FASII Antibiotics in Host Environments.Cell reports, 29 12
Nada Al-Mebairik, T. El-kersh, Y. Al-Sheikh, M. Marie (2016)
A review of virulence factors, pathogenesis, and antibiotic resistance in Staphylococcus aureusReviews in Medical Microbiology, 27
Lei Zhu, Jinshui Lin, Jin-cheng Ma, J. Cronan, Hai-Hong Wang (2009)
Triclosan Resistance of Pseudomonas aeruginosa PAO1 Is Due to FabV, a Triclosan-Resistant Enoyl-Acyl Carrier Protein ReductaseAntimicrobial Agents and Chemotherapy, 54
H. Bergler, S. Fuchsbichler, G. Högenauer, F. Turnowsky (1996)
The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.European journal of biochemistry, 242 3
N. Kaplan, M. Albert, D. Awrey, Elias Bardouniotis, J. Berman, Teresa Clarke, Mandy Dorsey, B. Hafkin, J. Ramnauth, V. Romanov, M. Schmid, R. Thalakada, J. Yethon, H. Pauls (2012)
Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI InhibitorAntimicrobial Agents and Chemotherapy, 56
D. Grandgirard, L. Furi, M. Ciusa, L. Baldassarri, D. Knight, I. Morrissey, C. Largiadèr, S. Leib, M. Oggioni (2015)
Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expressionBMC Genomics, 16
W. Mattheus, J. Masschelein, Ling-Jie Gao, P. Herdewijn, B. Landuyt, G. Volckaert, R. Lavigne (2010)
The kalimantacin/batumin biosynthesis operon encodes a self-resistance isoform of the FabI bacterial target.Chemistry & biology, 17 10
P. Walker, Christopher Williams, A. Weir, Luoyi Wang, J. Crosby, P. Race, T. Simpson, C. Willis, M. Crump (2019)
Control of beta-Branching in Kalimantacin Biosynthesis: Application of Direct Observe 13C NMR to Polyketide Programming.Angewandte Chemie
The enoyl‐acyl carrier protein reductase enzyme FabI is essential for fatty acid biosynthesis in Staphylococcus aureus and represents a promising target for the development of novel, urgently needed anti‐staphylococcal agents. Here, we elucidate the mode of action of the kalimantacin antibiotics, a novel class of FabI inhibitors with clinically‐relevant activity against multidrug‐resistant S. aureus. By combining X‐ray crystallography with molecular dynamics simulations, in vitro kinetic studies and chemical derivatization experiments, we characterize the interaction between the antibiotics and their target, and we demonstrate that the kalimantacins bind in a unique conformation that differs significantly from the binding mode of other known FabI inhibitors. We also investigate mechanisms of acquired resistance in S. aureus and identify key residues in FabI that stabilize the binding of the antibiotics. Our findings provide intriguing insights into the mode of action of a novel class of FabI inhibitors that will inspire future anti‐staphylococcal drug development.
Angewandte Chemie International Edition – Wiley
Published: Jun 22, 2020
Keywords: ; ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.